Osterman Mark T, Lichtenstein Gary R
Gary R. Lichtenstein, MD Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Division of Gastroenterology, 3rd Floor Ravdin Building, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA.
Curr Treat Options Gastroenterol. 2007 Jun;10(3):195-207. doi: 10.1007/s11938-007-0013-3.
Anti-tumor necrosis factor-alpha (anti-TNF) therapy has become a very important modality in the treatment of patients with inflammatory bowel disease. A number of anti-TNF medications have been investigated for this purpose, many via randomized controlled trials. Infliximab, the most studied of these agents, has shown impressive efficacy in the treatment of luminal and fistulizing Crohn's disease, as well as ulcerative colitis. Adalimumab and certolizumab have shown similar efficacy in Crohn's disease but have not yet been studied in ulcerative colitis. Less impressive results were seen in randomized controlled trials involving CDP-571, etanercept, or onercept for patients with Crohn's disease. Thalidomide and CNI-1493 have been evaluated only preliminarily in small, open-label pilot studies in patients with Crohn's disease. The future of anti-TNF therapy in inflammatory bowel disease is very bright, as exciting new developments continue to be made at a rapid pace.
抗肿瘤坏死因子-α（抗TNF）疗法已成为治疗炎症性肠病患者的一种非常重要的方式。为此，已经对多种抗TNF药物进行了研究，许多是通过随机对照试验进行的。英夫利昔单抗是这些药物中研究最多的，在治疗肠腔型和瘘管型克罗恩病以及溃疡性结肠炎方面显示出令人印象深刻的疗效。阿达木单抗和赛妥珠单抗在克罗恩病中显示出相似的疗效，但尚未在溃疡性结肠炎中进行研究。在涉及CDP-571、依那西普或昂瑞普的克罗恩病患者随机对照试验中，结果不太理想。沙利度胺和CNI-1493仅在针对克罗恩病患者的小型开放标签试验研究中进行了初步评估。随着令人兴奋的新进展继续迅速出现，抗TNF疗法在炎症性肠病中的前景非常光明。
